4RAMSAY MA, SAVEGE TM, SIMPSON BR, et al. Controlled sedation with alphaxalone -alphadolone [J]. Br Med J, 1974, 22:656-659.
5HANS G,ROBERT D.Transdermal buprenorphine-a critical appraisal of its role in pain management[J].J Pain Res,2009,2:117-134.
6PLOSKER GL.Buprenorphine 5,10 and 20 mug/h transdermal patch:a review of its use in the management of chronic non-malignant pain[J].Drugs,2011,71(18):2491-2509.
7VADIVELU N,HINES RL.Management of chronic pain in the elderly:focus on transdermal buprenorphine[J].Clin Interv Aging,2008,3(3):421-430.
8DAHAN A,YASSEN A,ROMBERG R,et al.Buprenorphine induces ceiling in respiratory depression but not in analgesia[J].Br J Anaesth,2006,96(5):627-632.
9WALSH SL,PRESTON KL,STITZER ML,et al.Clinical pharmacology of buprenorphine:ceiling effects at high doses[J].Clin Pharmacol Ther,1994,55(5):569-580.
10JOHNSON RE,FUDALA PJ,PAYNE R.Buprenorphine:considerations for pain management[J].J Pain Symptom Manage,2005,29(3):297-326.
